- Home
- QUIK vs ZURA Comparison
QUIK vs ZURA Comparison
Compare QUIK & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUIK
- ZURA
- Stock Information
- Founded
- QUIK 1988
- ZURA 2022
- Country
- QUIK United States
- ZURA United States
- Employees
- QUIK N/A
- ZURA N/A
- Industry
- QUIK Semiconductors
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QUIK Technology
- ZURA Health Care
- Exchange
- QUIK Nasdaq
- ZURA Nasdaq
- Market Cap
- QUIK 87.3M
- ZURA 69.9M
- IPO Year
- QUIK 1997
- ZURA N/A
- Fundamental
- Price
- QUIK $6.49
- ZURA $1.31
- Analyst Decision
- QUIK Strong Buy
- ZURA Buy
- Analyst Count
- QUIK 3
- ZURA 7
- Target Price
- QUIK $10.87
- ZURA $14.33
- AVG Volume (30 Days)
- QUIK 296.7K
- ZURA 708.2K
- Earning Date
- QUIK 08-12-2025
- ZURA 08-08-2025
- Dividend Yield
- QUIK N/A
- ZURA N/A
- EPS Growth
- QUIK N/A
- ZURA N/A
- EPS
- QUIK N/A
- ZURA N/A
- Revenue
- QUIK $18,768,000.00
- ZURA N/A
- Revenue This Year
- QUIK $11.58
- ZURA N/A
- Revenue Next Year
- QUIK $40.23
- ZURA N/A
- P/E Ratio
- QUIK N/A
- ZURA N/A
- Revenue Growth
- QUIK N/A
- ZURA N/A
- 52 Week Low
- QUIK $4.26
- ZURA $0.97
- 52 Week High
- QUIK $13.36
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- QUIK 60.73
- ZURA 59.63
- Support Level
- QUIK $5.99
- ZURA $1.00
- Resistance Level
- QUIK $7.24
- ZURA $1.45
- Average True Range (ATR)
- QUIK 0.41
- ZURA 0.10
- MACD
- QUIK 0.07
- ZURA 0.03
- Stochastic Oscillator
- QUIK 65.13
- ZURA 68.89
About QUIK QuickLogic Corporation
QuickLogic Corp provides programmable silicon and software platforms to enable its customers to develop custom hardware products in a fast time-to-market and cost-effective way. QuickLogic is a fabless semiconductor company with a product range: embedded FPGA (eFPGA) intellectual property (IP), low power, multi-core semiconductor system-on-chips (SoCs), discrete FPGAs, and AI software. The full range of platforms, software tools, and eFPGA IP enables the practical and efficient adoption of AI, voice, and sensor processing across Aerospace, and Defense, Consumer/Industrial IoT, and Consumer Electronics markets.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.